{"text": ["Lilly", "Confirms", "Date", "and", "Conference", "Call", "for", "First-Quarter", "2018", "Financial", "Results", "Announcement"], "created_at": "2018-04-04 20:49:00"}
{"text": ["Why", "Exelixis", "Will", "Triumph", "In", "Liver", "Cancer", "Battle", "With", "Eli", "Lilly"], "created_at": "2018-04-04 20:32:08"}
{"text": ["Health", "Care", "Sector", "Update", "for", "04/04/2018:", "SNN,AMRN,GSK,LLY"], "created_at": "2018-04-04 20:27:33"}
{"text": ["Health", "Care", "Sector", "Update", "for", "04/04/2018:", "SNN,AMRN,GSK,LLY"], "created_at": "2018-04-04 20:27:33"}
{"text": ["Health", "Care", "Sector", "Update", "for", "04/04/2018:", "AMRN,GSK,LLY"], "created_at": "2018-04-04 18:07:29"}
{"text": ["Health", "Care", "Sector", "Update", "for", "04/04/2018:", "AMRN,GSK,LLY"], "created_at": "2018-04-04 18:07:29"}
{"text": ["Running", "behind", "Gilead,", "Peninsula", "drug", "startup", "plots", "China", "dash", "for", "NASH"], "created_at": "2018-04-04 14:48:06"}
{"text": ["Lilly's", "Cyramza", "succeeds", "in", "late-stage", "liver", "cancer", "trial"], "created_at": "2018-04-04 14:20:51"}
{"text": ["Health", "Care", "Sector", "Update", "for", "04/04/2018:", "LLY,", "AMRN,", "GSK"], "created_at": "2018-04-04 13:27:36"}
{"text": ["Health", "Care", "Sector", "Update", "for", "04/04/2018:", "LLY,", "AMRN,", "GSK"], "created_at": "2018-04-04 13:27:36"}
{"text": ["Eli", "Lilly", "enters", "collaboration", "deal", "with", "Siligon", "for", "diabetes", "treatment,", "to", "take", "charge", "for", "in-process", "research"], "created_at": "2018-04-04 11:22:51"}
{"text": ["Eli", "Lilly", "enters", "collaboration", "deal", "with", "Siligon", "for", "diabetes", "treatment,", "to", "take", "charge", "for", "in-process", "research"], "created_at": "2018-04-04 11:22:51"}
{"text": ["Lilly", "and", "Sigilon", "Therapeutics", "Announce", "Strategic", "Collaboration", "to", "Develop", "Encapsulated", "Cell", "Therapies", "for", "the", "Treatment", "of", "Type", "1", "Diabetes"], "created_at": "2018-04-04 11:00:00"}
{"text": ["Fast-growing", "Cambridge", "biotech", "Sigilon", "inks", "$63M", "diabetes", "deal", "with", "Eli", "Lilly"], "created_at": "2018-04-04 11:00:00"}
{"text": ["Eli", "Lilly", "reports", "positive", "results", "in", "late-stage", "trial", "of", "liver", "cancer", "treatment"], "created_at": "2018-04-04 10:56:08"}
{"text": ["Eli", "Lilly", "reports", "positive", "results", "in", "late-stage", "trial", "of", "liver", "cancer", "treatment"], "created_at": "2018-04-04 10:56:08"}
{"text": ["Lilly", "Announces", "CYRAMZA\u00ae", "(ramucirumab)", "Phase", "3", "REACH-2", "Study", "in", "Second-Line", "Hepatocellular", "Carcinoma", "Patients", "Met", "Overall", "Survival", "Endpoint"], "created_at": "2018-04-04 10:45:00"}
{"text": ["Eli", "Lilly,", "Sigilon", "Announce", "Global", "Collaboration", "-", "Quick", "Facts"], "created_at": "2018-04-04 07:15:00"}
{"text": ["Eli", "Lilly,", "Sigilon", "Announce", "Global", "Collaboration", "-", "Quick", "Facts"], "created_at": "2018-04-04 07:15:00"}
{"text": ["Eli", "Lilly:", "CYRAMZA", "Phase", "3", "REACH-2", "Study", "Meets", "Primary", "Endpoint", "-", "Quick", "Facts"], "created_at": "2018-04-04 06:53:00"}
{"text": ["Eli", "Lilly:", "CYRAMZA", "Phase", "3", "REACH-2", "Study", "Meets", "Primary", "Endpoint", "-", "Quick", "Facts"], "created_at": "2018-04-04 06:53:00"}
